Biomedical approach in autism spectrum disorders—the importance of assessing inflammation

Tatjana Mijatovic; Dario Siniscalco; Krishnamurthy Subramanian; Eugene Bosmans; Vincent C. Lombardi; Kenny L. De Meirleir; Tatjana Mijatovic; Dario Siniscalco; Krishnamurthy Subramanian; Eugene Bosmans; Vincent C. Lombardi; Kenny L. De Meirleir

doi:10.3934/molsci.2018.3.173

AIMS Molecular Science

2018, Volume 5, Issue 3: 173-182. doi: 10.3934/molsci.2018.3.173

Previous Article Next Article

Communication Special Issues

Biomedical approach in autism spectrum disorders—the importance of assessing inflammation

1.
R.E.D. Laboratories, Z.1 Researchpark 100, B-1731 Zellik, Belgium
2.
Department of Experimental Medicine, University of Campania, 80138 Napoli, Italy
3.
Centre for Autism—La Forza del Silenzio, Caserta, 81036, Italy
4.
Italian Group for Studying Autism—GISA, Brescia, 25018, Italy
5.
Nevada Center for Biomedical Research, Reno, NV, 89557-0552, USA
6.
University of Nevada, Reno, School of Medicine, Department of Pathology, Reno, NV, 89557-0552, USA
7.
Himmunitas vzw, 1120 Brussels, Belgium

Received: 18 February 2018 Accepted: 03 July 2018 Published: 06 July 2018

Autism spectrum disorders (ASD) are severe heterogeneous neurodevelopmental disorders characterized by dysfunctions in social interaction and communication skills, repetitive and stereotypic verbal and nonverbal behaviors. Published findings have identified widespread changes in the immune systems of children with autism, at the systemic and cellular levels, suggesting that autism may, in fact, be a systemic disorder with connections to abnormal immune responses. Evaluating autism is hindered by a lack of specific biomarkers, making these pathologies difficult to diagnose. A critical priority for the future of ASD management is the identification of potential targets for the development of diagnostic and therapeutic strategies. The purpose of this brief report is to raise awareness regarding the involvement of different inflammatory processes in ASD and the need to assess them as a part of a biomedical evaluation. An extensive analysis of biomarkers relating to inflammation, immune dysfunctions, intestinal dysfunctions and infections will assist in the management of the autistic patient through a more personalized therapy.
- autism,
- inflammation,
- immune dysfunction,
- intestinal dysfunctions,
- biomedical evaluation
Citation: Tatjana Mijatovic, Dario Siniscalco, Krishnamurthy Subramanian, Eugene Bosmans, Vincent C. Lombardi, Kenny L. De Meirleir. Biomedical approach in autism spectrum disorders—the importance of assessing inflammation[J]. AIMS Molecular Science, 2018, 5(3): 173-182. doi: 10.3934/molsci.2018.3.173

Related Papers:

Abstract

Autism spectrum disorders (ASD) are severe heterogeneous neurodevelopmental disorders characterized by dysfunctions in social interaction and communication skills, repetitive and stereotypic verbal and nonverbal behaviors. Published findings have identified widespread changes in the immune systems of children with autism, at the systemic and cellular levels, suggesting that autism may, in fact, be a systemic disorder with connections to abnormal immune responses. Evaluating autism is hindered by a lack of specific biomarkers, making these pathologies difficult to diagnose. A critical priority for the future of ASD management is the identification of potential targets for the development of diagnostic and therapeutic strategies. The purpose of this brief report is to raise awareness regarding the involvement of different inflammatory processes in ASD and the need to assess them as a part of a biomedical evaluation. An extensive analysis of biomarkers relating to inflammation, immune dysfunctions, intestinal dysfunctions and infections will assist in the management of the autistic patient through a more personalized therapy.

References

[1]	Christensen DL, Bilder DA, Zahorodny W, et al. (2016) Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years-Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. MMWR Surveill Summ 65: 1–23.
[2]	Zablotsky B, Bramlett M, Blumberg SJ (2015) Factors associated with parental ratings of condition severity for children with autism spectrum disorder. Dis Health J 8: 626–634. doi: 10.1016/j.dhjo.2015.03.006
[3]	Hertz-Picciotto I, Delwiche L (2009) The rise in autism and the role of age at diagnosis. Epidemiology 20: 84–90. doi: 10.1097/EDE.0b013e3181902d15
[4]	First MB (2013) Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility. J Nerv Ment Dis 201: 727–729. doi: 10.1097/NMD.0b013e3182a2168a
[5]	Siniscalco D, Cirillo A, Bradstreet JJ, et al. (2013) Epigenetic findings in autism: New perspectives for therapy. Int J Environ Res Public Health 10: 4261–4273. doi: 10.3390/ijerph10094261
[6]	Siniscalco D (2013) Current findings and research prospective in autism spectrum disorders. Autism-Open Access S2: e001.
[7]	Siniscalco D (2014) The searching for autism biomarkers: A commentary on: A new methodology of viewing extra-axial fluid and cortical abnormalities in children with autism via transcranial ultrasonography. Front Hum Neurosci 8: 240.
[8]	Ashwood P, Krakowiak P, Hertz-Picciotto I, et al. (2011) Altered T cell responses in children with autism. Brain Behav Immun 25: 840–849. doi: 10.1016/j.bbi.2010.09.002
[9]	Suzuki K, Matsuzaki H, Iwata K, et al. (2011) Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders. PLoS One 6: e20470. doi: 10.1371/journal.pone.0020470
[10]	Okada K, Hashimoto K, Iwata Y, et al. (2007) Decreased serum levels of transforming growth factor-beta1 in patients with autism. Prog Neuro-Psychopharmacol Biol Psychiatry 31: 187–190. doi: 10.1016/j.pnpbp.2006.08.020
[11]	Ashwood P, Enstrom A, Krakowiak P, et al. (2008) Decreased transforming growth factor beta1 in autism: A potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 204: 149–153. doi: 10.1016/j.jneuroim.2008.07.006
[12]	Al-Ayadhi LY, Mostafa GA (2012) Elevated serum levels of interleukin-17A in children with autism. J Neuroinflammation 9: 158.
[13]	Inga Jacome MC, Morales Chacon LM, Vera CH, et al. (2016) Peripheral inflammatory markers contributing to comorbidities in autism. Behav Sci 6: 29.
[14]	Siniscalco D, Schultz S, Brigida AL, et al. (2018) Inflammation and neuro-immune dysregulations in autism spectrum disorders. Pharmaceuticals 11: E56. doi: 10.3390/ph11020056
[15]	El-Ansary A, Al-Ayadhi L (2012) Lipid mediators in plasma of autism spectrum disorders. Lipids Health Dis 11: 160. doi: 10.1186/1476-511X-11-160
[16]	Skorupka C, Amet L (2017) Autisme, un nouveau regard: Causes et solutions (French), French: Editions Mosaïque-Santé.
[17]	Rossignol DA, Frye RE (2012) Mitochondrial dysfunction in autism spectrum disorders: A systematic review and meta-analysis. Mol Psychiatry 17: 290–314. doi: 10.1038/mp.2010.136
[18]	Horvath K, Perman JA (2002) Autism and gastrointestinal symptoms. Curr Gastroenterol Rep 4: 251–258. doi: 10.1007/s11894-002-0071-6
[19]	Adams JB, Johansen LJ, Powell LD, et al. (2011) Gastrointestinal flora and gastrointestinal status in children with autism-comparisons to typical children and correlation with autism severity. BMC Gastroenterol 11: 22. doi: 10.1186/1471-230X-11-22
[20]	Finegold SM, Dowd SE, Gontcharova V, et al. (2010) Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 16: 444–453. doi: 10.1016/j.anaerobe.2010.06.008
[21]	Iovene MR, Bombace F, Maresca R, et al. (2017) Intestinal dysbiosis and yeast isolation in stool of subjects with autism spectrum disorders. Mycopathologia 182: 349–363. doi: 10.1007/s11046-016-0068-6
[22]	Critchfield JW, van Hemert S, Ash M, et al. (2011) The potential role of probiotics in the management of childhood autism spectrum disorders. Gastroenterol Res Pract 2011: 161358.
[23]	Siniscalco D, Antonucci N (2013) Involvement of dietary bioactive proteins and peptides in autism spectrum disorders. Curr Protein Pept Sci 14: 674–679.
[24]	Bransfield RC, Wulfman JS, Harvey WT, et al. (2008) The association between tick-borne infections, Lyme borreliosis and autism spectrum disorders. Med Hypotheses 70: 967–974. doi: 10.1016/j.mehy.2007.09.006
[25]	Kuhn M, Grave S, Bransfield R, et al. (2012) Long term antibiotic therapy may be an effective treatment for children co-morbid with Lyme disease and autism spectrum disorder. Med Hypotheses 78: 606–615. doi: 10.1016/j.mehy.2012.01.037
[26]	Vanuytsel T, Vermeire S, Cleynen I (2013) The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease. Tissue Barriers 1: e27321. doi: 10.4161/tisb.27321
[27]	Uribarri J, Oh MS, Carroll HJ (1998) D-lactic acidosis. A review of clinical presentation, biochemical features, and pathophysiologic mechanisms. Medicine 77: 73–82.
[28]	Nicolson GL, Gan R, Nicolson NL, et al. (2007) Evidence for Mycoplasma ssp., Chlamydia pneunomiae, and human herpes virus-6 coinfections in the blood of patients with autistic spectrum disorders. J Neurosci Res 85: 1143–1148.
[29]	Careaga M, Van de Water J, Ashwood P (2010) Immune dysfunction in autism: A pathway to treatment. Neurotherapeutics 7: 283–292. doi: 10.1016/j.nurt.2010.05.003

Reader Comments

Your name:*

Email:*
© 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)